

BRITISH JOURNAL OF PHARMACOLOGY

The *British Journal of Pharmacology* welcomes contributions in all fields of experimental pharmacology including neuroscience, biochemical, cellular and molecular pharmacology. The Board of Editors represents a wide range of expertise and ensures that well-presented work is published as promptly as possible, consistent with maintaining the overall quality of the journal.

Edited for the British Pharmacological Society by

A.T. Birmingham
(Chairman)

R.W. Horton W.A. Large
(Secretaries)

Editorial Board

P.I. Aaronson *London*
J.A. Angus *Melbourne, Australia*
G.W. Bennett *Nottingham*
T.P. Blackburn *Harlow*
N.G. Bowery *London*
W.C. Bowman *Glasgow*
S.D. Brain *London*
K.D. Butler *Horsham*
M. Caulfield *London*
R. Chess-Williams *Sheffield*
T. Cocks *Melbourne, Australia*
S.J. Coker *Liverpool*
R.A. Coleman *Ware*
Helen M. Cox *London*
A.J. Cross *London*
V. Crunelli *Cardiff*
T.C. Cunnane *Oxford*
F. Cunningham *London*
A. Dickenson *London*
J.R. Docherty *Dublin*
A. Dray *London*
L. Edvinsson *Lund, Sweden*
G. Edwards *Manchester*
J.M. Edwardson *Cambridge*
R.M. Eglen *Palo Alto, USA*
P.C. Emson *Cambridge*
A.C. Foster *San Diego, USA*
J.R. Fozard *Basle, Switzerland*
Allison D. Fryer *Baltimore, USA*

J.P. Gallagher *Galveston, USA*
Sheila M. Gardiner *Nottingham*
C.J. Garland *Bristol*
A. Gibson *London*
M.A. Giembycz *London*
W.R. Giles *Calgary, Canada*
R.G. Goldie *Perth, Australia*
R.J. Griffiths *Connecticut, USA*
R.W. Gristwood *Cambridge*
Judith M. Hall *London*
D.W.P. Hay *Philadelphia, USA*
P.G. Hellewell *London*
P.E. Hicks *Edinburgh*
S.J. Hill *Nottingham*
K. Hillier *Southampton*
S.M.O. Hourani *Guildford*
J.C. Hunter *Palo Alto, USA*
E.J. Johns *Birmingham*
R.S.G. Jones *Oxford*
C.C. Jordan *Ware*
P.A.T. Kelly *Edinburgh*
D.A. Kendall *Nottingham*
C. Kennedy *Glasgow*
P. Leff *Loughborough*
A.T. McKnight *Cambridge*
C.A. Maggi *Florence, Italy*
Janice M. Marshall *Birmingham*
G. Martin *Beckenham*
W. Martin *Glasgow*

A. Mathie *London*
D.N. Middlemiss *Harlow*
P.K. Moore *London*
C.D. Nicholson *Oss, The Netherlands*
H. Osswald *Tübingen, Germany*
F.L. Pearce *London*
J.D. Pearson *London*
A.G. Renwick *Southampton*
P.J. Roberts *Bristol*
G.J. Sanger *Harlow*
W.C. Sessa *Connecticut, USA*
P. Sneddon *Glasgow*
K. Starke *Freiburg, Germany*
R.J. Summers *Melbourne, Australia*
P.V. Taberner *Bristol*
J. Tamargo *Madrid, Spain*
C. Thiemermann *London*
M.D. Tricklebank *Basle, Switzerland*
T.J. Verbeuren *Suresnes, France*
R.R. Vollmer *Pittsburgh, USA*
K.J. Watling *Boston, USA*
A.H. Weston *Manchester*
J. Westwick *Bath*
Eileen Winslow *Riom, France*
E.H.F. Wong *Milan, Italy*
B. Woodward *Bath*

Corresponding Editors

P.R. Adams *Stony Brook, U.S.A.*
C. Bell *Dublin*
F.E. Bloom *La Jolla, U.S.A.*
A.L.A. Boura *Newcastle, Australia*
N.J. Dun *Toledo, U.S.A.*
R.F. Furchgott *New York, U.S.A.*
T. Godfraind *Brussels, Belgium*
S.Z. Langer *Paris, France*

R.J. Miller *Chicago, U.S.A.*
R.C. Murphy *Denver, U.S.A.*
E. Muscholl *Mainz, Germany*
R.A. North *Geneva, Switzerland*
M. Otsuka *Tokyo, Japan*
M.J. Rand *Melbourne, Australia*
S. Rosell *Södertälje, Sweden*
P. Seeman *Toronto, Canada*

L. Szekeres *Szeged, Hungary*
B. Uvnäs *Stockholm, Sweden*
P.A. Van Zwieten *Amsterdam, Netherlands*
V.M. Varagić *Belgrade, Yugoslavia*
G. Velo *Verona, Italy*
Wang Zhen Gang *Beijing, China*
M.B.H. Youdim *Haifa, Israel*

Submission of manuscripts: Manuscripts (two copies) should be sent to The Editorial Office, British Journal of Pharmacology, St. George's Hospital Medical School, Cranmer Terrace, London SW17 0RE.

Authors should consult the Instructions to Authors and the Nomenclature Guidelines for Authors in Vol. 114, 245–255. These Instructions and Guidelines also appear with the journal Index for Volumes 111–113, 1994. A checklist of the essential requirements is summarised in each issue of the journal, or as the last page of the issue.

Whilst every effort is made by the publishers and editorial committee to see that no inaccurate or misleading data, opinion or statement appears in this Journal, they and the *British Pharmacological Society* wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor or advertiser concerned. Accordingly, the *British Pharmacological Society*, the publishers and the editorial committee and their respective employees, officers and agents accept no liability whatsoever for the consequences of any such inaccurate or misleading data, opinion or statement.

Q. Li, J. Zhang, M. Pfaffendorf & P.A. van Zwieten. Comparative effects of angiotensin II and its degradation products angiotensin III and angiotensin IV in rat aorta **2963**

J.M. Lundberg & A. Modin. Inhibition of sympathetic vasoconstriction in pigs *in vivo* by the neuropeptide Y-Y₁ receptor antagonist BIBP 3226 **2971**

V. Ralevic, P. J. Milla & G. Burnstock. Effects of chronic vitamin E deficiency on vascular function - a study of sympathetic nerves, smooth muscle and endothelium of the mesenteric arterial bed of the rat **2983**

B. Costall & R.J. Naylor. Behavioural interactions between 5-hydroxytryptophan, neuroleptic agents and 5-HT receptor antagonists in modifying rodent responding to aversive situations **2989**

F. Abe, M. Mitsui, H. Karaki & M. Endoh. Calcium compartments in vascular smooth muscle cells as detected by aequorin signal **3000**

P. Charlesworth, I. Jacobson & C. D. Richards. Pentobarbitone modulation of NMDA receptors in neurones isolated from the rat olfactory brain **3005**

M. Fujimoto, M. Munakata & N. Akaike. Dual mechanisms of GABA_A response inhibition by β -lactam antibiotics in the pyramidal neurones of the rat cerebral cortex **3014**

U. Wenzel, D.T. Thwaites & H. Daniel. Stereoselective uptake of β -lactam antibiotics by the intestinal peptide transporter **3021**

S.J. Hughes & M. Hollingsworth. Cellular localization of the inhibitory action of relaxin against uterine spasm **3028**

J. Chen, M.L. Champa-Rodriguez & D.F. Woodward. Identification of a prostanoid FP receptor population producing endothelium-dependent vasorelaxation in the rabbit jugular vein **3035**

S.M. Gardiner, P.A. Kemp, J.E. March & T. Bennett. Enhancement of the haemodynamic effects of N^G-monomethyl-L-arginine by transforming growth factor- β_1 in conscious, normal, but not endotoxaemic, rats **3042**

C. Prior, L. Tian, A.I. El Mallah, L. Young & J.M. Ward. Neuromuscular blocking profile of the vecuronium analogue, Org-9487, in the rat isolated hemidiaphragm preparation **3049**

Y. Takiguchi, F. Asai, K. Wada, H. Hayashi & M. Nakashima. Antithrombotic effect of a novel recombinant hirudin analogue, CX-397, in a rat arterial thrombosis model **3056**

H. Nawrath, D. Bäumner, J. Rupp & H. Oelert. The ineffectiveness of the NO-cyclic GMP signaling pathway in the atrial myocardium **3061**

M.D. Randall. The involvement of ATP-sensitive potassium channels and adenosine in the regulation of coronary flow in the isolated perfused rat heart **3068**

V. Ralevic, P.J. Milla & G. Burnstock. Effects of chronic vitamin E deficiency and a high polyunsaturated fatty acid diet on rat mesenteric arterial function **3075**

The *British Journal of Pharmacology* is published by Stockton Press, a division of Macmillan Press Ltd. It is the official publication of the British Pharmacological Society.

Scope The *British Journal of Pharmacology* is published twice a month. It welcomes contribution in all fields of experimental pharmacology including neuroscience, biochemical, cellular and molecular pharmacology. The Board of Editors represents a wide range of expertise and ensures that well-presented work is published as promptly as possible, consistent with maintaining the overall quality of the journal.

This journal is covered by Current Contents, Excerpta Medica, BIOSIS, CABS, CINAHL and Index Medicus.

Editorial Manuscripts (plus two copies) and all editorial correspondence should be sent to: The Editorial Office, *British Journal of Pharmacology*, St George's Hospital Medical School, Cranmer Terrace, London SW17 0RE, UK. Tel: +44 (0)181 767 6765; Fax: +44 (0)181 767 5645.

Advertisements Enquiries concerning advertisements should be addressed to: Michael Rowley, Hasler House, High Street, Great Dunmow, Essex CM6 1AP, UK. Tel: +44 (0)1371 874613; Fax: +44 (0)1371 872273.

Publisher All business correspondence, supplement enquiries and reprint requests should be addressed to *British Journal of Pharmacology*, Stockton Press, Houndmills, Basingstoke, Hampshire RG21 2XS, UK. Tel: +44 (0)1256 29242; Fax: +44 (0)1256 810526. Publisher: Marija Vukovojac. Production Controller: Nicci Crawley.

Subscriptions - EU/Rest of World Subscription price per annum (3 volumes, 24 issues) £620, rest of world £820 (Airmail), £685 (Surface mail) or equivalent in any other currency. Orders must be accompanied by remittance. Cheques should be made payable to Macmillan Magazines and sent to: The Subscription Department Macmillan Press Ltd, Houndmills, Basingstoke, Hampshire RG21 2XS, UK. Where appropriate, subscribers may make payments into UK Post Office Giro Account No. 519 2455. Full details must accompany the payment. Subscribers from EC territories should add sales tax at the local rate.

Subscriptions - USA USA subscribers call toll free 1-800-221-2123 or send check/money order/credit card details to: Stockton Press, 49, West 24th Street, New York, NY 10010; Tel: 212 627 5757, Fax: 212 627 9256. USA annual subscription rates: \$1230 Airmail; \$1030 Surface (Institutional/Corporate); \$225 (Individual making personal payment).

British Journal of Pharmacology (ISSN 0007-1188) is published twice a month by Macmillan Press Ltd, c/o Mercury Airfreight International Ltd, 2323 Randolph Avenue, Avenel, NJ 07001, USA. Subscription price for institutions is \$1030 per annum (surface). 2nd class postage is paid at Rahway NJ. Postmaster: send address corrections to Macmillan Press Ltd, c/o Mercury Airfreight International Ltd, 2323 Randolph Avenue, Avenel NJ 07001.

Reprints of any article in this journal are available from Stockton Press, Houndmills, Basingstoke, Hampshire RG21 2XS, UK. Tel: +44 (0)1256 29242; Fax: +44 (0)1256 810526.

Copyright © 1995 Stockton Press
ISSN 0007-1188

All rights of reproduction are reserved in respect of all papers, articles, illustrations, etc., published in this journal in all countries of the world.

All material published in this journal is protected by copyright, which covers exclusive rights to reproduce and distribute the material. No material published in this journal may be reproduced or stored on microfilm or in electronic, optical or magnetic form without the written authorisation of the Publisher.

Authorisation to photocopy items for internal or personal use of specific clients, is granted by Stockton Press for libraries and other users registered with the Copyright Clearance Center (CCC) Transaction Reporting Service, provided that the base fee of \$12.00 per copy is paid directly to CCC, 21 Congress St., Salem, MA 01970, USA. 0007-1188/95 \$12.00 + \$0.00.

Apart from any fair dealing for the purposes of research or private study, or criticism or review, as permitted under the Copyright, Designs and Patent Act 1988, this publication may be reproduced, stored or transmitted, in any form or by any means, only with the prior permission in writing of the publishers, or in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency.

1996 Keystone Symposia

on Molecular and Cellular Biology

The Cell Cycle

Organizers: Steven I. Reed and Joan Ruderman

January 11-17, 1996; Taos, New Mexico

Breast and Prostate Cancer: Basic Mechanisms

Organizers: Mina Bissell and Timothy Thompson

January 29-February 4, 1996; Taos, New Mexico

Gene Therapy for Hematopoietic Stem Cells in Genetic Disease and Cancer

Organizers: Stefan Karlsson, Keith Humphries and Paul Tolstoshev

February 4-10, 1996; Taos, New Mexico

Write to: Keystone Symposia • Drawer 1630 • Silverthorne, CO 80498

Phone: (970) 262-1230 • Fax: (970) 262-1525 • E-mail: symposia@keystone.org

June 20 – 21 1996

London UK

Festschrift in honour of Professor Sir Colin Dollery

International symposium – Clinical Pharmacology:
Inflammation–Hypertension–Metabolism &
Toxicity–Drug Regulation–Drug Development & Discovery.

Further information from D Boland, Department of Clinical
Pharmacology, Royal Postgraduate Medical School,
London W12 0NN.

Tel: 0181 740 3220 Fax: 0181 749 3439

PREPARATION OF MANUSCRIPTS

Authors are strongly recommended to read the full *Instructions to Authors* and *Nomenclature Guidelines for Authors* (*Br. J. Pharmacol.* 1995, **114**, 245–255) before submitting a manuscript for publication in the *British Journal of Pharmacology*. The manuscript and cover letter should be checked against the following list before mailing.

The original and one copy of the manuscript must be supplied. Manuscripts must be typed in double-line spacing on one side of A4 paper, in type not smaller than 12 characters per inch or 10 point. Both copies to include Tables and a set of labelled Figures. One set of Figures without numbers or letters is also to be included. The text to be arranged in the following subsections:

1. **Title**—To have no more than 150 characters on a separate page, which should also include a Short Title (50 characters maximum) and the name and address of the author for correspondence.
2. **Summary**—To be arranged in numbered paragraphs (Full Papers) or a single paragraph (Special Reports).
—to include aims, principal results and conclusions.
—to include Key words (10 maximum) at end of summary.
3. **Introduction**—To contain concise statements of the problem and the aims of the investigation.
4. **Methods**—To have brief but adequate account of the procedures; *full names of drugs (including those referred to by manufacturer's code)*, sources of drugs and statistical tests to be stated.
5. **Results**—To have no repetition of data in Figures, Tables and text.
6. **Discussion**—Findings and conclusions to be placed in context of other relevant work.
NB Simple repetition of results and unwarranted speculation are not acceptable.
7. **Acknowledgements**—Sources of support. Sources of drugs not widely available commercially.
8. **References**—All references in the text to be included in the Reference List and *vice versa*. References in alphabetical order with complete citations; Journals publishing 'in press' papers identified.

References to manuscripts submitted to other journals but not yet accepted are not allowed.

9. **Tables**—Each on a separate page and prepared in accordance with current requirements of the Journal.
10. **Figures**—Both labelled and non-labelled Figures to be prepared in accordance with current requirements of the Journal (see *Instructions to Authors*, 1994, **114**, 245–251) and provided with Figure Number and Authors' names on back (*in pencil*).
—each legend to be typed on a separate page and carrying keys to symbols.
—keys to symbols and histograms must not appear on the figures themselves, but in the respective legends.
—'box style' figures are not in keeping with the Journal style; line drawings etc must have only left-hand and bottom axes.
11. **Manuscripts**—To be accompanied by a declaration signed by each author that
 - (a) results are original
 - (b) approval of all persons concerned has been given to submit manuscripts for consideration (see also 12b)
 - (c) the same material is neither 'in press' (i.e. is in proof or has definitely been accepted for publication) nor under consideration elsewhere. Furthermore it will not be submitted or published elsewhere before a decision has been reached by the Editorial Board of the *British Journal of Pharmacology* and will not be submitted elsewhere if accepted by the *British Journal of Pharmacology*.
 - (d) Copyright assignment is included.
12. **Cover letter**—To state clearly
 - (a) Corresponding author's full postal address, telephone, telex or Fax number
 - (b) where appropriate, that *either* ethical approval has been given for investigation *or* Company or Institutional permission to publish work has been received.
13. **Reminder**—Packaging to be sufficiently robust to protect Figures and to withstand mailing.

Failure to comply with *Instructions to Authors* may lead to substantial delays in processing, review and publication and may even jeopardize acceptance of the manuscript.

NOMENCLATURE

Authors are reminded that accepted receptor and associated terminology is laid out in *Nomenclature Guidelines for Authors*, as published in the *British Journal of Pharmacology*, *Br. J. Pharmacol.*, 1995, **114**, 253–255.

SPECIAL REPORTS

The purpose of *Special Reports* is to provide rapid publication for **new** and **important** results which the Editorial Board considers are likely to be of special pharmacological significance. *Special Reports* will have publication priority over all other material and so authors are asked to consider carefully the status of their work before submission.

In order to speed publication there is normally no revision allowed beyond very minor typographical or grammatical corrections. If significant revision is required, the Board may either invite rapid re-submission or, more probably, propose that it be re-written as a Full Paper and be re-submitted for consideration. In order to reduce delays, proofs of *Special Reports* will be sent to authors but **essential corrections must reach the Production Office within 48 hours of receipt**. Authors should ensure that their submitted material conforms exactly to the following requirements.

Special Reports should normally occupy no more than two printed pages of the Journal; two illustrations (Figures or Tables, with legends) are permitted. As a guideline, with type face of 12 pitch and double-line spacing, a page of A4 paper could contain about 400 words. The absolute maximum length of the *Special Report* is 1700 words. For each Figure or Table, please deduct 200 words. The manuscript should comprise a Title page with key words (maximum of 10), a Summary consisting of a single short paragraph, followed by Introduction, Methods, Results, Discussion and References (maximum of 10). In all other respects, the requirements are the same as for Full Papers (see current 'Instructions to Authors').

SPECIAL REPORT

M. D'Amico & T. D. Warner. Involvement of endothelin in the pressor response following injection of NMDA to the periaqueductal gray area of rats 2787

PAPERS

E.J. Fletcher, J. Church, K. Abdel-Hamid & J.F. MacDonald. Blockade by *sigma* site ligands of *N*-methyl-D-aspartate-evoked responses in rat and mouse cultured hippocampal pyramidal neurones 2791

J. Church & E.J. Fletcher. Blockade by *sigma* site ligands of high voltage-activated Ca^{2+} channels in rat and mouse cultured hippocampal pyramidal neurones 2801

L. Metzinger, A.-C. Passaquin, W.J. Leijendekker, P. Poindron & U.T. Rüegg. Modulation by prednisolone of calcium handling in skeletal muscle cells 2811

C. Souccar, M. do Carmo Goncalo, A.J. Lapa, L.R.P. Troncone, I. Lebrun & F. Magnoli. Blockade of acetylcholine release at the motor endplate by a polypeptide from the venom of *Phoneutria nigriventer* 2817

N.J. Toms, D.E. Jane, H.-W. Tse & P.J. Roberts. Characterization of metabotropic glutamate receptor-stimulated phosphoinositide hydrolysis in rat cultured cerebellar granule cells 2824

H. Oida, T. Namba, Y. Sugimoto, F. Ushikubi, H. Ohishi, A. Ichikawa & S. Narumiya. *In situ* hybridization studies of prostacyclin receptor mRNA expression in various mouse organs 2828

K.M.L. Cross, S.D. Jane, A.E. Wild, R.C. Foreman & J.E. Chad. Activation of nicotinic acetylcholine receptors expressed in quail fibroblasts: effects on intracellular calcium 2838

C. Thiemermann, H. Ruetten, C.-C. Wu & J.R. Vane. The multiple organ dysfunction syndrome caused by endotoxin in the rat: attenuation of liver dysfunction by inhibitors of nitric oxide synthase 2845

N.A. Lavidis. Effect of morphine on the nerve terminal impulse and transmitter release from sympathetic varicosities innervating the mouse vas deferens 2852

N.A. Lavidis. Effect of chronic morphine treatment on transmitter release from sympathetic varicosities of the mouse vas deferens 2860

G. Kolios, Z. Brown, R.L. Robson, D.A.F. Robertson & J. Westwick. Inducible nitric oxide synthase activity and expression in a human colonic epithelial cell line, HT-29 2866

L. Ny, B. Larsson, P. Alm, P. Ekström, J. Fahrenkrug, J. Hannibal & K.-E. Andersson. Distribution and effects of pituitary adenylate cyclase activating peptide in cat and human lower oesophageal sphincter 2873

H.G.J. van Mil, C.J.M. Kerkhof & J. Siegenbeek van Heukelom. Modulation of the isoprenaline-induced membrane hyperpolarization of mouse skeletal muscle cells 2881

J.M. Dickenson & S.J. Hill. Coupling of an endogenous 5-HT_{1B}-like receptor to increases in intracellular calcium through a pertussis toxin-sensitive mechanism in CHO-K1 cells 2889

R.B. Barlow, S.M. Bond, A.G. Branthwaite, O. Jackson, D.S. McQueen, K.M. Smith & P.J. Smith. Selective blockade of M₂ and M₃ muscarinic receptors by hexahydrobenzyl-fouradapine and a comparison with zamifenacin 2897

R.A. Armstrong. Investigation of the inhibitory effects of PGE₂ and selective EP agonists on chemotaxis of human neutrophils 2903

C. Ho, J. Hicks & M. W. Salter. A novel P₂-purinoceptor expressed by a subpopulation of astrocytes from the dorsal spinal cord of the rat 2909

A. Mizuta, Y. Takano, K. Honda, R. Saito, T. Matsumoto & H.-o. Kamiya. Nitric oxide is a mediator of tachykinin NK₃ receptor-induced relaxation in rat mesenteric artery 2919

R. Pabla, P. Bland-Ward, P.K. Moore & M.J. Curtis. An endogenous protectant effect of cardiac cyclic GMP against reperfusion-induced ventricular fibrillation in the rat heart 2923

L. Negri, G. Improta, R. Lattanzi, R. L. Potenza, F. Luchetti & P. Melchiorri. Interaction between the μ -agonist dermorphin and the δ -agonist [D-Ala², Glu⁴]deltorphin in supraspinal antinociception and δ -opioid receptor binding 2931

I.A. Greenwood & W.A. Large. Comparison of the effects of fenamates on Ca-activated chloride and potassium currents in rabbit portal vein smooth muscle cells 2939

R. Dickinson, W.R. Lieb & N.P. Franks. The effects of temperature on the interactions between volatile general anaesthetics and a neuronal nicotinic acetylcholine receptor 2949

M.G. Persson, S.G. Friberg, L.E. Gustafsson & P. Hedqvist. The promotion of patent airways and inhibition of antigen-induced bronchial obstruction by endogenous nitric oxide 2957

Q. Li, J. Zhang, M. Pfaffendorf & P.A. van Zwieten. Comparative effects of angiotensin II and its degradation products angiotensin III and angiotensin IV in rat aorta 2963

J.M. Lundberg & A. Modin. Inhibition of sympathetic vasoconstriction in pigs *in vivo* by the neuropeptide Y-Y₁ receptor antagonist BIBP 3226 2971

V. Ralevic, P. J. Milla & G. Burnstock. Effects of chronic vitamin E deficiency on vascular function - a study of sympathetic nerves, smooth muscle and endothelium of the mesenteric arterial bed of the rat 2983

B. Costall & R.J. Naylor. Behavioural interactions between 5-hydroxytryptophan, neuroleptic agents and 5-HT receptor antagonists in modifying rodent responding to aversive situations 2989

F. Abe, M. Mitsui, H. Karaki & M. Endoh. Calcium compartments in vascular smooth muscle cells as detected by aequorin signal 3000

P. Charlesworth, I. Jacobson & C.D. Richards. Pentobarbitone modulation of NMDA receptors in neurones isolated from the rat olfactory brain 3005

M. Fujimoto, M. Munakata & N. Akaike. Dual mechanisms of GABA_A response inhibition by β -lactam antibiotics in the pyramidal neurones of the rat cerebral cortex 3014

U. Wenzel, D.T. Thwaites & H. Daniel. Stereoselective uptake of β -lactam antibiotics by the intestinal peptide transporter 3021

S.J. Hughes & M. Hollingsworth. Cellular localization of the inhibitory action of relaxin against uterine spasm 3028

J. Chen, M.L. Champa-Rodriguez & D.F. Woodward. Identification of a prostanoid FP receptor population producing endothelium-dependent vasorelaxation in the rabbit jugular vein 3035

S.M. Gardiner, P.A. Kemp, J.E. March & T. Bennett. Enhancement of the haemodynamic effects of N^G-monomethyl-L-arginine by transforming growth factor- β ₁ in conscious, normal, but not endotoxaemic, rats 3042

C. Prior, L. Tian, A.I. El Mallah, L. Young & J. M. Ward. Neuromuscular blocking profile of the vecuronium analogue, Org-9487, in the rat isolated hemidiaphragm preparation 3049

Y. Takiguchi, F. Asai, K. Wada, H. Hayashi & M. Nakashima. Antithrombotic effect of a novel recombinant hirudin analogue, CX-397, in a rat arterial thrombosis model 3056

H. Nawrath, D. Bäumner, J. Rupp & H. Oelert. The ineffectiveness of the NO-cyclic GMP signaling pathway in the atrial myocardium 3061

M.D. Randall. The involvement of ATP-sensitive potassium channels and adenosine in the regulation of coronary flow in the isolated perfused rat heart 3068

V. Ralevic, P.J. Milla & G. Burnstock. Effects of chronic vitamin E deficiency and a high polyunsaturated fatty acid diet on rat mesenteric arterial function 3075